234 related articles for article (PubMed ID: 20148715)
21. IkappaB kinase beta (IKKbeta/IKK2/IKBKB)--a key molecule in signaling to the transcription factor NF-kappaB.
Schmid JA; Birbach A
Cytokine Growth Factor Rev; 2008 Apr; 19(2):157-65. PubMed ID: 18308615
[TBL] [Abstract][Full Text] [Related]
22. Curcumin downregulates the constitutive activity of NF-kappaB and induces apoptosis in novel mouse melanoma cells.
Marín YE; Wall BA; Wang S; Namkoong J; Martino JJ; Suh J; Lee HJ; Rabson AB; Yang CS; Chen S; Ryu JH
Melanoma Res; 2007 Oct; 17(5):274-83. PubMed ID: 17885582
[TBL] [Abstract][Full Text] [Related]
23. Regulation and function of IKK and IKK-related kinases.
Häcker H; Karin M
Sci STKE; 2006 Oct; 2006(357):re13. PubMed ID: 17047224
[TBL] [Abstract][Full Text] [Related]
24. NF-kappaB and IKK as therapeutic targets in cancer.
Kim HJ; Hawke N; Baldwin AS
Cell Death Differ; 2006 May; 13(5):738-47. PubMed ID: 16485028
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of potassium currents as a pharmacologic target for investigation in chronic lymphocytic leukemia.
Biderman B; Marakhonov A; Skoblov M; Birerdinc A; Nohelty E; Page S; Khomenkov V; Chandhoke V; Sudarikov A; Nikitin E; Baranova A
Drug News Perspect; 2010 Dec; 23(10):625-31. PubMed ID: 21180648
[TBL] [Abstract][Full Text] [Related]
26. Blockade of nuclear factor-kappaB signaling pathway and anti-inflammatory activity of cardamomin, a chalcone analog from Alpinia conchigera.
Lee JH; Jung HS; Giang PM; Jin X; Lee S; Son PT; Lee D; Hong YS; Lee K; Lee JJ
J Pharmacol Exp Ther; 2006 Jan; 316(1):271-8. PubMed ID: 16183703
[TBL] [Abstract][Full Text] [Related]
27. A selective small molecule IkappaB Kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells.
Wen D; Nong Y; Morgan JG; Gangurde P; Bielecki A; Dasilva J; Keaveney M; Cheng H; Fraser C; Schopf L; Hepperle M; Harriman G; Jaffee BD; Ocain TD; Xu Y
J Pharmacol Exp Ther; 2006 Jun; 317(3):989-1001. PubMed ID: 16525037
[TBL] [Abstract][Full Text] [Related]
28. NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia.
Breccia M; Alimena G
Expert Opin Ther Targets; 2010 Nov; 14(11):1157-76. PubMed ID: 20858024
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of NF-κB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells.
Cosimo E; McCaig AM; Carter-Brzezinski LJ; Wheadon H; Leach MT; Le Ster K; Berthou C; Durieu E; Oumata N; Galons H; Meijer L; Michie AM
Clin Cancer Res; 2013 May; 19(9):2393-405. PubMed ID: 23532892
[TBL] [Abstract][Full Text] [Related]
30. Targeting NF-kappaB for colorectal cancer.
Sakamoto K; Maeda S
Expert Opin Ther Targets; 2010 Jun; 14(6):593-601. PubMed ID: 20367537
[TBL] [Abstract][Full Text] [Related]
31. Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor.
Vaisitti T; Gaudino F; Ouk S; Moscvin M; Vitale N; Serra S; Arruga F; Zakrzewski JL; Liou HC; Allan JN; Furman RR; Deaglio S
Haematologica; 2017 Nov; 102(11):1878-1889. PubMed ID: 28860341
[TBL] [Abstract][Full Text] [Related]
32. Direct Rel/NF-κB inhibitors: structural basis for mechanism of action.
Ouk S; Liou ML; Liou HC
Future Med Chem; 2009 Dec; 1(9):1683-707. PubMed ID: 21425986
[TBL] [Abstract][Full Text] [Related]
33. The role of NF-kappaB in lymphoid malignancies.
Packham G
Br J Haematol; 2008 Oct; 143(1):3-15. PubMed ID: 18573107
[TBL] [Abstract][Full Text] [Related]
34. The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells.
Godbersen JC; Humphries LA; Danilova OV; Kebbekus PE; Brown JR; Eastman A; Danilov AV
Clin Cancer Res; 2014 Mar; 20(6):1576-89. PubMed ID: 24634471
[TBL] [Abstract][Full Text] [Related]
35. NF-κB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions.
Mansouri L; Papakonstantinou N; Ntoufa S; Stamatopoulos K; Rosenquist R
Semin Cancer Biol; 2016 Aug; 39():40-8. PubMed ID: 27491692
[TBL] [Abstract][Full Text] [Related]
36. The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.
Gupta SV; Hertlein E; Lu Y; Sass EJ; Lapalombella R; Chen TL; Davis ME; Woyach JA; Lehman A; Jarjoura D; Byrd JC; Lucas DM
Clin Cancer Res; 2013 May; 19(9):2406-19. PubMed ID: 23515408
[TBL] [Abstract][Full Text] [Related]
37. STAT3 and NF-κB cooperatively control in vitro spontaneous apoptosis and poor chemo-responsiveness in patients with chronic lymphocytic leukemia.
Liu FT; Jia L; Wang P; Wang H; Farren TW; Agrawal SG
Oncotarget; 2016 May; 7(22):32031-45. PubMed ID: 27074565
[TBL] [Abstract][Full Text] [Related]
38. Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.
Hartmann TN; Pleyer L; Desch P; Egle A; Greil R
Discov Med; 2009 Oct; 8(42):157-64. PubMed ID: 19833065
[TBL] [Abstract][Full Text] [Related]
39. BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.
Asslaber D; Wacht N; Leisch M; Qi Y; Maeding N; Hufnagl C; Jansko B; Zaborsky N; Villunger A; Hartmann TN; Greil R; Egle A
Clin Cancer Res; 2019 Mar; 25(6):1901-1912. PubMed ID: 30487125
[TBL] [Abstract][Full Text] [Related]
40. NF-κB as a potential therapeutic target in microbial diseases.
Vitiello M; Galdiero M; Finamore E; Galdiero S; Galdiero M
Mol Biosyst; 2012 Apr; 8(4):1108-20. PubMed ID: 22311336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
